Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Profit After Tax (2016 - 2025)

Historic Profit After Tax for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $338.7 million.

  • United Therapeutics' Profit After Tax rose 957.62% to $338.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 1447.48%. This contributed to the annual value of $1.2 billion for FY2024, which is 2135.46% up from last year.
  • United Therapeutics' Profit After Tax amounted to $338.7 million in Q3 2025, which was up 957.62% from $309.5 million recorded in Q2 2025.
  • United Therapeutics' 5-year Profit After Tax high stood at $338.7 million for Q3 2025, and its period low was $28.3 million during Q1 2021.
  • Its 5-year average for Profit After Tax is $229.1 million, with a median of $240.9 million in 2023.
  • Its Profit After Tax has fluctuated over the past 5 years, first tumbled by 7944.81% in 2021, then surged by 74770.32% in 2022.
  • United Therapeutics' Profit After Tax (Quarter) stood at $112.2 million in 2021, then increased by 17.74% to $132.1 million in 2022, then skyrocketed by 64.35% to $217.1 million in 2023, then skyrocketed by 38.78% to $301.3 million in 2024, then rose by 12.41% to $338.7 million in 2025.
  • Its last three reported values are $338.7 million in Q3 2025, $309.5 million for Q2 2025, and $322.2 million during Q1 2025.